

COMPOSITION

TELPART-AM TABLETS

Each uncoated tablet contains telmisartan 40 mg and amlodipine besylate equivalent to amlodipine 5 mg

INDICATIONS

For the treatment of essential hypertension in adults only.

DOSAGE AND ADMINISTRATION

Dosage should be individualized. The recommended dose is one tablet of **TELPART-AM TABLETS** once daily. If necessary, the dose may be increased to two tablets of **TELPART-AM TABLETS** once daily at least 2 weeks. Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. The maximum recommended dose of **TELPART-AM TABLETS** two tablets once daily.

Dose-titration guided by clinical effect:

A patient whose blood pressure is not adequately controlled with telmisartan or amlodipine monotherapy may be switched to the combination therapy.

Patients treated with 10 mg amlodipine who experience any dose-limiting adverse reactions such as edema, may be switched to **TELPART-AM TABLETS** once daily, reducing the dose of amlodipine without reducing the overall expected antihypertensive response.

Initial Therapy:

A patient may be initiated on **TELPART-AM TABLETS** tablets if it is unlikely that control of blood pressure would be achieved with a single agent. The usual starting dose of **TELPART-AM TABLETS** is 40/5 mg once daily. Patients requiring larger blood pressure reductions may be started on two tablets of **TELPART-AM TABLETS** once daily .

Initial therapy with **TELPART-AM TABLETS** is not recommended in patients ≥ 75 years old or with hepatic impairment.

Correct imbalances of intravascular volume- or salt-depletion, before initiating therapy with **TELPART-AM TABLETS**.

Replacement Therapy:

For convenience, patients receiving telmisartan and amlodipine from separate tablets may instead wish to receive combination tablets containing the same component doses. When substituting for individual components, increase the dose of **TELPART-AM TABLETS** .

Dosing in Specific Populations

Renal Impairment

No initial dosage adjustment is required for patients with mild or moderate renal impairment. Titrate slowly in patients with severe renal impairment.

Hepatic Impairment

In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients with hepatic impairment.

Patients 75 Years of Age and Older

In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients 75 years of age and older.

CONTRAINDICATIONS

TELPART-AM TABLETS is contraindicated in patients with known hypersensitivity to telmisartan or Amlodipine or any other component of this product.

PACKAGING INFORMATION

TELPART-AM TABLETSAlu-ALu pack of 10 tablets

